Clinical Trials Browser

Phase 1/2 × Carcinoma, Neuroendocrine × Paclitaxel × Clear all

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1/2 Recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma